The ongoing First in Human Trial (N=30) has enrolled 15 moderate to severe dry eye patients in an open label, single arm study. It included a single treatment in one eye and a follow-up period of 3 months, in which safety and efficacy endpoints are evaluated.

Study sites include Hadassah Ein Karem and Shaare Zedek Medical Centers in Jerusalem, and Wolfson Medical center in Holon, Israel.